Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10916413 | 0.81 | MGLL (0.55) | CYP1A2CYP2C19KDM4EALDH1A1MAPT | |
| SCHEMBL6905606 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP2C19GAAKDM4EALDH1A1 | |
| SCHEMBL30963679 | 0.77 | CYP1A2 (0.53) | CYP1A2CYP2C19GAAKDM4EALDH1A1 | |
| SCHEMBL30758082 | 0.77 | CYP1A2 (0.53) | CYP1A2CYP2C19GAAKDM4EALDH1A1 | |
| SCHEMBL13824739 | 0.77 | CYP1A2 (1.00) | CYP1A2CYP2C19GAAKDM4EALDH1A1 | |
| SCHEMBL2612166 | 0.73 | NPSR1 (0.47) | CYP1A2CYP2C19KDM4EALDH1A1MAPT | |
| SCHEMBL5270640 | 0.73 | HSD17B10 (0.48) | CYP1A2CYP2C19GAAKDM4EALDH1A1 | |
| SCHEMBL12365098 | 0.73 | ALDH1A1 (0.42) | CYP1A2CYP2C19ALDH1A1MAPTMGLL | |
| SCHEMBL29827105 | 0.73 | HSD17B10 (0.48) | CYP1A2CYP2C19GAAKDM4EALDH1A1 | |
| SCHEMBL10983420 | 0.72 | MGLL (0.62) | ALDH1A1MAPTMGLLHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109678776-A | The preparation method of 3- aryl succinimide class compound | 苏州大学 | 2019-04-26 | — | — | CN | claimed |
| CN-1249033-C | Cyclic amp-specific phosphodiesterase inhibitors | ICOS CORP (US) | 2006-04-05 | — | — | CN | claimed |
| CN-1434799-A | Cyclic amp-specific phosphodiesterase inhibitors | ICOS CORP (US) | 2003-08-06 | — | — | CN | claimed |
| US-5415893-A | Dispersion of electrically conductive particles in a dispersing medium | DSM N.V. (NL) | 1995-05-16 | — | — | US | claimed |
| JP-61183873-A | — | — | None | — | — | JP | disclosed |
| CN-106083686-B | The method of alpha-brominated acetophenone oxime ether synthesis 2,4- diaryl pyrrole class compound | 苏州大学 | 2019-01-22 | — | — | CN | disclosed |
| CN-104918939-B | Purine inhibitors of human phosphatidylinositol 3-kinase | 默沙东公司 | 2018-08-28 | — | — | CN | disclosed |
| CN-108349962-A | Substituted pyrazole and pyrrole compounds and methods of using the same for inhibiting translation initiation and treating diseases and disorders associated therewith | 班塔姆制药有限责任公司 | 2018-07-31 | — | — | CN | disclosed |
| US-20180064718-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | ABIONYX PHARMA (FR) | 2018-03-08 | — | — | US | disclosed |
| US-9827228-B2 | Opioid receptor modulators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-11-28 | — | — | US | disclosed |
| US-9713619-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-07-25 | — | — | US | disclosed |
| US-9714219-B2 | Sulfonylaminobenzamide compounds | NOVARTIS TIERGESUNDHEIT AG (CH) | 2017-07-25 | — | — | US | disclosed |
| US-5019949-A | Solid electrolytic capacitor | SANYO ELECTRIC CO., LTD. (JP) | 1991-05-28 | — | — | US | disclosed |
| US-4933106-A | NEUTRALIZED POLYISOTHIANAPHTHENE OR DERIVATIVE AND ANIONIC POLYMER ELECTROLYTE DOPANT | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0342998-A2 | Process for manufacturing an electrode for a solid electrolytic capacitor | Sanyo Electric Co., Ltd (JP) | 1989-11-23 | — | — | EP | disclosed |
| EP-0269090-A1 | Highly conductive polymer composition and process for producing the same | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1988-06-01 | — | — | EP | disclosed |
| US-4731311-A | Electrically conductive material and secondary battery using the electrically conductive material | SANYO ELECTRIC CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
| EP-0219063-A2 | Process of manufacturing an electrically conductive material and a secondary battery using the electrically conductive material | Sanyo Electric Co., Ltd (JP) | 1987-04-22 | — | — | EP | disclosed |
| JP-S61183873-A | SECONDARY CELL | SHOWA DENKO KK | 1986-08-16 | — | — | JP | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064718-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | CYP1A2 1769/4885CYP2C19 1577/4885GAA 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.